Glaucoma Pipeline Market 2017 Covering Therapeutics Development Stage and Drug Profiles Analysis

PUNE, India, May 24, 2017 /PRNewswire-iReach/ -- RnRMarketResearch.com adds "Glaucoma - Pipeline Review, H1 2017" to its store providing an overview of the Glaucoma therapeutic pipeline with comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects.

Complete report on H1 2017 pipeline review of Glaucoma spread across 280 pages is available at http://www.rnrmarketresearch.com/glaucoma-pipeline-review-h1-2017-market-report.html.

Glaucoma Pipeline report also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companiesdiscussed in this Glaucoma Pipeline Review H1 2017 report include AC Immune SA, Advanced Refractive Technologies Inc, Aerie Pharmaceuticals Inc, Allergan Plc, Altacor Ltd, Amarantus Bioscience Holdings Inc, Amgen Inc, Annexon Inc, Astellas Pharma Inc, Bausch & Lomb Inc, BioAxone BioSciences Inc, Bionure Farma SL, Can-Fite BioPharma Ltd, Clearside BioMedical Inc, D. Western Therapeutics Institute Inc, Dompe Farmaceutici SpA, Elsalys Biotech SAS, F. Hoffmann-La Roche Ltd, Gene Signal International SA, Gilead Sciences Inc, Glaukos Corp, Graybug Vision Inc, Han Wha Pharma Co Ltd, Handok Inc, Icon Bioscience Inc, ID Pharma Co Ltd, InMed Pharmaceuticals Inc, Inotek Pharmaceuticals Corp, Ironwood Pharmaceuticals Inc, Isarna Therapeutics GmbH, Kukje Pharmaceutical Industry Co Ltd, Laboratoires Thea SA, Laboratorios SALVAT SA, Laboratorios Sophia SA de CV, Lee's Pharmaceutical Holdings Ltd, Lexicon Pharmaceuticals Inc, Merck & Co Inc, Mimetogen Pharmaceuticals Inc, Nemus Bioscience Inc, Neurim Pharmaceuticals Ltd, NicOx SA, NoNO Inc, Novaliq GmbH, Ocular Therapeutix Inc, Oculis ehf, Ohr Pharmaceutical Inc, Profarma, Q BioMed Inc, Quark Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc, Santen Pharmaceutical Co Ltd, Senju Pharmaceutical Co Ltd, Shire Plc, SK Biopharmaceuticals Co Ltd, Sun Pharma Advanced Research Company Ltd, Sun Pharmaceutical Industries Ltd, Sylentis SAU

Get Discount on This Report Athttp://www.rnrmarketresearch.com/contacts/discount?rname=1001942  (This report is available at upto 25% Discount till 02 June 2017.)

Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow of the optic nerve. The most important risk factors include age, elevated eye pressure, African ancestry, thin cornea, family history of glaucoma. Signs and symptoms include eye pain, nausea and vomiting (accompanying the severe eye pain), sudden onset of visual disturbance, often in low light, blurred vision and reddening of the eye. 

Glaucoma (Ophthalmology) pipeline guide reviews of key players involved in therapeutic development for Glaucoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 10, 22, 8, 56, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 10 and 5 molecules, respectively.

Direct Purchase of This Research Report at http://www.rnrmarketresearch.com/contacts/purchase?rname=1001942.

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Glaucoma and reviews pipeline therapeutics for Glaucoma by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Glaucoma therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Glaucoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Glaucoma.

Table of Contents

Glaucoma - Overview

Glaucoma - Therapeutics Development

Glaucoma - Therapeutics Assessment

Glaucoma - Companies Involved in Therapeutics Development

Glaucoma - Drug Profiles

Glaucoma - Dormant Projects

Glaucoma - Discontinued Products

Glaucoma - Product Development Milestones

List of Tables.

About Us:

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Media Contact:Ritesh Tiwari, RnRMarketResearch, +1-888-391-5441, sales@rnrmarketresearch.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE RnRMarketResearch